327 related articles for article (PubMed ID: 32782768)
1. A rare atypical chronic myeloid leukemia BCR-ABL1 negative with concomitant
Gao T; Yu C; Xia S; Liang T; Gu X; Liu Z
Ther Adv Hematol; 2020; 11():2040620720927105. PubMed ID: 32782768
[TBL] [Abstract][Full Text] [Related]
2. Trametinib: Could It Be a Promising Drug to Treat Atypical Chronic Myeloid Leukemia?
Elsayed M; Harry S; Nanua S; Zaidi S; Habib MH; Raza S
Cureus; 2022 Jul; 14(7):e26619. PubMed ID: 35949766
[TBL] [Abstract][Full Text] [Related]
3. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
Szuber N; Orazi A; Tefferi A
Am J Hematol; 2024 Apr; ():. PubMed ID: 38644693
[TBL] [Abstract][Full Text] [Related]
4. Current and evolving understanding of atypical chronic myeloid leukemia.
Schwartz LC; Mascarenhas J
Blood Rev; 2019 Jan; 33():74-81. PubMed ID: 30078497
[TBL] [Abstract][Full Text] [Related]
5. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
[TBL] [Abstract][Full Text] [Related]
6. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
[TBL] [Abstract][Full Text] [Related]
7. Atypical Chronic Myeloid Leukemia: Where Are We Now?
Crisà E; Nicolosi M; Ferri V; Favini C; Gaidano G; Patriarca A
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962122
[TBL] [Abstract][Full Text] [Related]
8. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
[TBL] [Abstract][Full Text] [Related]
9. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
10. Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm.
Fend F; Horn T; Koch I; Vela T; Orazi A
Leuk Res; 2008 Dec; 32(12):1931-5. PubMed ID: 18555525
[TBL] [Abstract][Full Text] [Related]
11.
Linder K; Iragavarapu C; Liu D
Biomark Res; 2017; 5():33. PubMed ID: 29225884
[TBL] [Abstract][Full Text] [Related]
12. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
13. The implication of identifying JAK2 ( V617F ) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis.
Olsen RJ; Dunphy CH; O'Malley DP; Rice L; Ewton AA; Chang CC
J Hematop; 2008 Sep; 1(2):111-7. PubMed ID: 19669209
[TBL] [Abstract][Full Text] [Related]
14. Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients.
De Roeck L; Michaux L; Debackere K; Lierman E; Vandenberghe P; Devos T
Hematology; 2018 Dec; 23(10):785-792. PubMed ID: 29993347
[TBL] [Abstract][Full Text] [Related]
15. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
[TBL] [Abstract][Full Text] [Related]
17. Primary myelofibrosis with concurrent
Zhou FP; Wang CC; Du HP; Cao SB; Zhang J
World J Clin Cases; 2020 Nov; 8(22):5618-5624. PubMed ID: 33344552
[TBL] [Abstract][Full Text] [Related]
18. Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.
Shi XB; Jiang JF; Jin FX; Cheng W
World J Clin Cases; 2019 May; 7(9):1087-1092. PubMed ID: 31123683
[TBL] [Abstract][Full Text] [Related]
19. [Investigation of Laboratory and Clinical Feature in the Patients with Myeloproliferative Neoplasm Co-expression of BCR-ABL1 and JAK2 V617F].
Yuan XG; Wan RT; Zhao XW; Yang XZ; Xiao J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1236-1241. PubMed ID: 34362508
[TBL] [Abstract][Full Text] [Related]
20. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
